The latest webinar presentations from OmniaBio’s cell and gene therapy subject matter experts.
iPSC-based therapy dilemmas explored: overcoming hurdles for future success
Induced pluripotent stem cell (iPSC)-based therapies offer advantages in their potential to address clinical applicability and scalable manufacturing to meet patient demand. As the number of iPSC-based therapies in clinical development is increasing, the industry is seeing significant advancement following decades of development efforts. Despite these noteworthy strides, there are still many existing dilemmas to address for sustained progress and commercial viability.
In this webinar, we will delve into these critical aspects to reshape the landscape of iPSC-based therapies:
- Explore strategies to expedite therapy development and accelerate speed to market;
- Evaluate the existing licensing and royalty stacking paradigm in iPSC technology and discuss innovative approaches to address challenges and opportunities;
- Examine existing product characterization best practices and avenues for enhancing standardization across the sector; and,
- Debate the necessity of clean room environments and the impact on manufacturing efficiency and product quality.
